Helicobacter Pylori Diagnostic Market Size, Share & Trends Analysis Report By Technology (Immunoassays, POC, Molecular Diagnostics), By End User (Hospitals, Diagnostics Laboratories, Clinics), By Region, And Segment Forecasts, 2024-2031

The Global Helicobacter Pylori Diagnostic Market Size is valued at 559.89 million in 2023 and is predicted to reach 911.50 million by the year 2031 at a 6.31% CAGR during the forecast period for 2024-2031.

Helicobacter pylori (H. pylori), an aerobic, gram-negative bacterium, is frequently found in the stomach. It is vital to the preservation of the stomach environment. The spiral-shaped bacteria that cause H. infection with pylori penetrate the esophagus, small intestine, and stomach lining, increasing the risk of gastric cancer, peptic ulcers, and chronic gastritis. 

One of the most significant factors that will contribute to the growth of the helicobacter pylori diagnostic market is the rising number of patients with gastric ulcers. Other important factors include the rising prevalence of geriatrics worldwide, the rising demand for point-of-care testing devices, the growing adoption of non-invasive testing, and the simple accessibility of diagnostic tests.

On the other hand, growing technological development, increased innovations, and increased product approvals will all contribute to expanding the helicobacter pylori diagnostic market during the period covered by the projections above. In emerging nations, there are expected to be market restrictions on developing the helicobacter pylori diagnostic market due to a lack of experienced specialists and knowledge about the advantages of testing. 

Competitive Landscape:

Some of the in the Helicobacter Pylori Diagnostic Market players are:

• Abbott
• Agilent Technologies, Inc.
• Alpha Laboratories
• Avanos Medical Devices.
• Biohit Oyj
• Bio-Rad Laboratories
• Cardinal Health, Inc.
• Certest Biotec
• CorisBioconcept SPRL
• EKF Diagnostics
• Epitope Diagnostics
• Exalenz Bioscience Ltd.
• Hoffmann-La Roche Ltd
• Gulf Coast Scientific
• Halyard Health, Inc.
• Helena Laboratories Corporation
• HORIBA Europe GmbH
• Medline Industries, Inc.
• Meridian Bioscience, Inc.
• QIAGEN
• Quest Diagnostics
• Quidel Corporation.
• Sekisui Diagnostics
• Takara Bio Inc.
• Thermo Fisher Scientific, Inc. 

Market Segmentation:

The Helicobacter pylori diagnostic market is segmented by technology and end user. The technology segment includes Immunoassays, POC, and Molecular Diagnostics. By the end user, the market is segmented into Hospitals, Diagnostics Laboratories, and Clinics.

Based On Technology, The Immunoassay Segment Is Accounted As A Significant Contributor In The Helicobacter Pylori Diagnostic Market

The immunoassay segment had the most significant market share and is expected to continue to dominate the market over the coming years. For the detection of antibodies, a number of cutting-edge technologies are used, such as enzyme immunoassays. Serology, fast urease tests, and urea breath tests are a few of the indirect tests. Although molecular diagnostics represented the second-largest market share, POC tests still accounted for some of the most frequently employed methods.

The Hospitals Segment Witnessed Growth At A Rapid Rate

Due to the simplicity of disease presentation, the accessibility of doctors, and the increased occurrence of diseases such as duodenal ulcers, stomach cancer, gastritis, gastric ulcers, and infections of the small intestine, hospitals held the most significant market share.

The North America Helicobacter Pylori Diagnostic Market Holds A Significant Revenue Share In The Region

Throughout the projection period, North America is expected to dominate the global market for helicobacter pylori diagnostics. Infectious disease instances, awareness of contagious diseases, and introduction of new products are all contributing causes to the growth. For instance, Biomerica Inc. announced in June 2021 that it had inked a five-year exclusive distribution agreement with a Canadian partner to distribute and market Biomerica's innovative and exclusive Helicobacter pylori test, known as hp+detect. Helicobacter pylori infection, the most common cause of duodenal and gastric ulcers and a risk factor for stomach cancer, have been targeted by developing the hp+detect product. Therefore, such occurrences are projected to fuel market growth in the North American area.

Helicobacter Pylori Diagnostic Market Report Scope: